title: Intrastromal injection of bevacizumab in patients with corneal neovascularization.
abstract: Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization.
authors.affiliation: Vision Institute, Department of Ophthalmology, Universidade Federal de São Paulo - UNIFESP - São Paulo (SP), Brazil.
authors.forename: Ana Carolina Cabreira
authors.initials: AC
authors.lastname: Vieira
authors.forename: Ana Luisa
authors.initials: AL
authors.lastname: Höfling-Lima
authors.forename: José Álvaro P
authors.initials: JÁ
authors.lastname: Gomes
authors.forename: Denise de
authors.initials: Dd
authors.lastname: Freitas
authors.forename: Michel Eid
authors.initials: ME
authors.lastname: Farah
authors.forename: Rubens
authors.initials: R
authors.lastname: Belfort
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab